USPSTF releases guidelines on breast-cancer chemoprevention.
Jane
J
Bradbury
D016588:Anticarcinogenic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000517:prevention & control*; D005260:Female; D006801:Humans; D017410:Practice Guidelines as Topic; D020849:Raloxifene Hydrochloride / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D013629:Tamoxifen / Q000009:adverse effects / Q000627:therapeutic use*; D014481:United States
D016588:Anticarcinogenic Agents; D013629:Tamoxifen; D020849:Raloxifene Hydrochloride